Based on our improved novel
Salmonella vaccine delivery platform, we optimized the recombinant attenuated Salmonella Typhimurium vaccine (RASV) χ12094 to deliver multiple Y. pestis antigens. These included LcrV196 (amino acids, 131 to 326), Psn encoded on pYA5383 and F1 encoded in the chromosome, their synthesis did not cause adverse effects on bacterial growth. Oral immunization with χ12094(pYA5383) simultaneously stimulated high antibody titers to LcrV, Psn and F1 in mice and presented complete protection against both subcutaneous (s.c.) and intranasal (i.n.) challenges with high lethal doses of Y. pestis CO92. Moreover, no deaths or other disease symptoms were observed in SCID mice orally immunized with χ12094(pYA5383) over a 60 day period. Therefore, the trivalent S. Typhimurium-based live vaccine shows promise for a next-generation plague vaccine.